The first award, made to a five-partner consortium led by the company ReNeuron, will bring together science and industry experts to develop new stem cell products for commercial use in treating neurodegenerative diseases such as stroke, Huntington’s disease and Parkinson’s disease, as well as other illnesses including diabetes, blindness and cardiac disease.

RegenTec will be working on the development of delivery systems that provide a supportive environment for stem cells. Once administered, the stem cells either encourage the growth of tissue by triggering the body’s own repair processes or themselves begin to grow and form new tissue.

The second project, led by the company NovaThera, will aim to develop our understanding of the way in which cells grow and develop into specific cells for different functions. The research, which will initially focus on cells to repair bone, lung and liver tissue, will look at ways in which this growth can be effectively controlled or manipulated.

Link to University of Nottingham's Press Release

Read More